Cryosite Limited (CTE) AI Stock Analysis

• Market Cap: AU$36.36M
• Dividend Yield: 2.68%
• Average Volume (3M): 4.63K
• Price to Earnings (P/E): 19.9
• Beta (1Y): -0.56
• Revenue Growth: 1.86%
• EPS Growth: 16.10%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.04
• Shares Outstanding: 48,809,563
• 10 Day Avg. Volume: 13,274
• 30 Day Avg. Volume: 4,635
• PEG Ratio: 6.04
• Price to Book (P/B): 10.97
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 25.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: AU$1.00 ▲(35.14%Upside)

Cryosite Limited demonstrates a solid financial performance, particularly in cash flow generation and profitability, which are key strengths. However, the company's balance sheet shows concerns regarding financial leverage, posing potential risks. Technical analysis reflects a bearish trend, but the valuation is reasonable, with an attractive dividend yield. Overall, the stock presents a balanced profile with opportunities and risks, warranting a cautious but optimistic outlook.

Cryosite Limited Business Overview & Revenue Model

Company Description

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.

How the Company Makes Money

Cryosite Limited generates revenue primarily through its service offerings in the biostorage and biomanagement sectors. Its key revenue streams include fees from clients for storing biological samples, such as cord blood and tissue, which are often collected for potential future medical use. Additionally, the company earns income by providing specialized biorepository services to support clinical trials and research initiatives, offering storage, logistics, and management of biological specimens. Significant partnerships with healthcare providers, research institutions, and clinical trial organizations enhance its service reach and contribute to its earnings.

Cryosite Limited Financial Statement Overview

Summary

Cryosite Limited presents a robust financial performance with strong revenue growth and profitability improvements. The company excels in cash flow generation, reflecting its operational efficiency. However, the balance sheet indicates financial leverage concerns due to decreasing equity and a rising debt-to-equity ratio, which may pose long-term risks if not addressed. Overall, Cryosite demonstrates promising financial health with a need for careful leverage management.

Income Statement

Cryosite Limited shows a strong income statement with consistent revenue growth, evident in a 5.7% increase from 2023 to 2024. The company maintains a healthy gross profit margin of 63.4% in 2024. Net profit margin improved to 14.6% in 2024 from 11.8% in 2023, reflecting effective cost management. EBITDA margin also increased to 23.0%, signaling robust operational efficiency. However, the EBIT margin at 16.3% indicates room for further improvement in operational profitability.

Balance Sheet

Cryosite Limited's balance sheet reveals a challenging equity position, with stockholders' equity declining significantly over the period. The debt-to-equity ratio increased, indicating higher leverage. The equity ratio is low at 7.4%, reflecting potential solvency risks. Despite these challenges, the company has maintained a negative net debt, highlighting strong liquidity with cash reserves exceeding total debt.

Cash Flow

The cash flow statement is a strong point for Cryosite Limited, with a substantial increase in free cash flow by 106% from 2023 to 2024. Operating cash flow also improved significantly, more than doubling to $2.9 million. The company effectively generates cash relative to net income, indicating efficient cash management and operational performance.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	12.85M	12.61M	11.94M	11.76M	10.02M	8.92M
Gross Profit	7.89M	7.99M	6.48M	6.27M	5.31M	3.51M
EBITDA	2.99M	3.04M	2.34M	2.45M	1.65M	1.15M
Net Income	1.83M	1.84M	1.41M	1.36M	652.57K	1.48M
Balance Sheet
Total Assets	19.09M	19.71M	22.65M	21.50M	21.99M	23.50M
Cash, Cash Equivalents and Short-Term Investments	4.49M	4.70M	5.73M	5.34M	3.88M	4.06M
Total Debt	2.36M	2.44M	2.61M	849.76K	1.07M	1.26M
Total Liabilities	17.77M	18.26M	19.86M	19.64M	21.17M	23.35M
Stockholders Equity	1.31M	1.45M	2.78M	1.86M	819.23K	154.88K
Cash Flow
Free Cash Flow	2.20M	2.44M	1.19M	1.63M	80.07K	396.54K
Operating Cash Flow	2.76M	2.90M	1.49M	2.49M	476.96K	1.31M
Investing Cash Flow	-481.00K	727.00K	-1.33M	-863.19K	-396.89K	-909.85K
Financing Cash Flow	-3.72M	-3.50M	-768.00K	-148.99K	-260.78K	-254.60K

Cryosite Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Neutral. The current price of 0.74 is above the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.75, and below the 200-day MA of 0.80, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.06 is Neutral, neither overbought nor oversold. The STOCH value of 57.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CTE.

Cryosite Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	66 Neutral	AU$36.36M	19.87	87.09%	2.68%	1.86%	16.10%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%
LDX	45 Neutral	AU$20.96M	―	-51.49%	―	80.84%	57.59%
IIQ	45 Neutral	AU$42.42M	―	-39.07%	―	26.07%	0.85%
RHY	41 Neutral	AU$15.10M	―	-71.10%	―	―	76.17%
BDX	40 Neutral	AU$23.79M	―	-104.23%	―	―	-17.26%
MAP	39 Underperform	AU$42.75M	―	-33.42%	―	158.37%	36.73%

Cryosite Limited Corporate Events

Cryosite Director Increases Stake with New Share Acquisition

Cryosite Limited has announced a change in the director’s interest in securities. Mark Kerr, a director of the company, has acquired 75,000 fully paid ordinary shares through on-market purchases, increasing his total holdings. This acquisition reflects a continued investment by the director in the company, potentially signaling confidence in the company’s future performance.

Cryosite Limited Announces Director’s Share Acquisition

Cryosite Limited announced a change in the director’s interest, with Mark Kerr acquiring an additional 231,453 fully paid ordinary shares, bringing his total to 7,231,453 shares. This change, conducted through both off-market and on-market trades, reflects a strategic move in the company’s governance structure, potentially impacting its market positioning and stakeholder interests.